Title of Invention

NEW PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

Abstract

1. Process for the industrial synthesis of penndopril of formula (I) and pharmaceutically acceptable salts thereof, characterised in that the benzyl ester of formula (IV): wherein Bn represents the benzyl group, is reacted with the compound of formula (V): in ethyl acetate, in the presence of an amount of from 0.4 to 0.6 mol of 1-hydroxybenzotriazole per mol of compound of formula (TV) eniployed and in the presence of an amount of from 1 to 1.2 mol of dicyclohexylcarbodiimide per mol of compoxmd of formula (IV) employed, in the absence of triethylamine or in the presence of an amount of triethylamine that is less than or equal to 1 mol per mol of compound of formula (IV) employed, at a temperature of from 20 to 77°C, to yield, after isolation, the compound of formula (VI) : wherein Bn represents the benzyl group, the carboxylic group of the heterocycle of which is deprotected by catalytic hydrogenation to yield perindopril of formula (I), which is converted, if desired, into a pharmaceutically acceptable salt.

Full Text

FORM 2 THE PATENTS ACT 1970 [39 OF 1970] COMPLETE SPECIFICATION [See Section 10] "NEW PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF" LES* LABORATOIRES SERVIER, of 12 Place de la Defense, 92415 Courbevoie Cedex, France, The following specification particularly describes the nature of the invention and the manner in which it is to be performed :- The present invention relates to a process for the industrial synthesis of perindopril of formula (T): H and pharmaceutically acceptable salts thereof. Perindopril, and also pharmaceutically acceptable salts thereof, and more especially the tert-butylamine salt thereof, have valuable pharmacological properties. Their principal property Hes in the inhibition of the enzyme that converts angiotensin I (or kininase 11), which enables on the one hand prevention of the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II (vasoconstrictor) and oh the other hand prevention of the degradation of bradykinin (vasodilator) to inactive peptide. ■ Those two actions contribute to the beneficial effects of perindopril in cardiovascular disorders, especially arterial hypertension and cardiac insufficiency. Perindopril, its preparation and its therapeutic use have been described in European Patent Specification EP 0 049 658. Given the pharmaceutical interest in that compoimd, it is important to be able to obtain it by an effective industrial synthesising process that can readily be applied on an industrial scale, yielding perindopril in a good yield and, especially, with an excellent degree of purit) The Patent Specification EP 0 308 341 describes the industrial synthesis of perindopril by the coupling of (25',3aS',7aS)-octahydroindole-2-carboxyhc acid benzyl ester with N-[(5)-l- carboxybutyl]-(5)-alanine ethyl ester, followed by deprotection of the carboxylic group of the heterocycle by catalytic hydrogenation. That process has the advantage of yielding perindopril in a good yield from starting materials for which industrial synthesis has already been described. However, the purity of the perindopril obtained by that process is not satisfactory, and necessitates a purification step in order to obtain perindopril of a quality that would allow its use as a pharmaceutical active ingredient. Indeed, under the conditions described in that patent specification the perindopril obtained is contaminated by significant amounts of the impurities of formulae (II) and (III): H H (II) (HI)- The Applicant has now developed a new industrial synthesising process that yields perindopril in a degree of purity that is compatible with its use as a pharmaceutical active ingredient, the levels of impurities of formulae (II) and (III) being less than 0.2 % and 0.1 %, respectively. More specifically, the present invention relates to a process for the industrial synthesis of perindopril which is characterised in that the benzyl ester of formula (IV): wherein Bn Tepresents the benzyl group, is reacted with the compound of formula (V) : in ethyl acetate, in the presence of an amount of from 0.4 to 0.6 mol of 1-hydroxybenzotriazoIe per mol of compound of formula (IV) employed and in the presence of an amount of from 1 to 1.2 mol of dicyclohexylcarbodiimide per mol of compound of formula (IV) employed, in the absence of triethylamine or in the presence of an amonnt of triethylamine that is less than or equal to 1 mol per mol of compound of formula (IV) employed, preferably less than or equal to 0.25 mol per mol of compound of formula (IV) employed, at a temperature of from 20 to 77°C, to yield, after isolation, the compound of formula (VI) wherein Bn represents the benzyl group, the carboxyhc group of the heterocycle of which is deprotected by catalytic hydrogenation to yield perindopril of formula (I), which is converted, if desired, into a pharmaceutically acceptable salt, such as the tert-butylamine salt. The process is of particular interest for the following reasons : The coupling in alkahne medium of the benzyl ester of formula (IV) with the compound of formula (V) has been described in the Patent Specification EP 0 308 341 but, under the conditions described (the use of 3 mols of compound of formula (V), 3 mol of triethylamine, 3.8 mol of 1-hydroxybenzotriazole and 2.9 mol of dicyclo-hexylcarbodiimide per mol of compound of formula (IV) employed), numerous secondary products are formed. In particular, the compound of formula (VI) obtained contains in significant amounts (5 to 15 %) the impurities of formulae (VII) et (VIII) which, when debenzylation is carried out, result in the impurities of formulae (II) and (III) (VII) (VIII). - The Applicant has found, unexpectedly, that the reduction, or even omission, of triethylamine in the coupling step, has made it possible to restrict the levels of impurities of formulae (VII) and (VIII) in the compound of formula (VI) to less than 1.5%. The catalytic hydrogenation of the compound of formula (VI) so obtained yields perindopril of far better purity, and in particular with levels of impurities of formulae (II) and (III) of less than 0.2 % and 0.1 %, respectively. - In addition, the reduction, in the coupling step, of the amount of compound of formula (V), of 1-hydroxybenzotriazole and of dicyclohexylcarbodiimide, enables a yield of compound of formula (VI) to be obtained that is as good as that obtained with larger amounts of reagents, thus making the process far more advantageous on an industrial scale. The Examples below illustrate the invention but do not hmit it in any way. Examvle 1: Benl (2S,3aS, 7aS)-l-{(2S)-2-l(lS)-l-(etha:carbonyl)-butylammo]-pmpianylJ-octahydFa-lH-Mole-2-carboxplate: There are introduced into a reactor, with stirring, 1 kg of (25,3aS',7a5)-octahydroindole-2-carboxylic acid benzyl ester paratoluenesulfonate, 0.06 kg of triethylamine, 4.6 litres of ethyl acetate and then, after stirring for 10 minutes at ambient temperature, 0.52 kg of N-[(5)-ethoxycarbonyl-l-butyl]-(5)-alanine, 0.15 kg of 1-hydroxybenzotriazole and 0.5 kg of dicylohexylcarbodiimide. The heterogeneous mixture is then brought to 30°C for 3 hours while stirring well, and is subsequently cooled to 0°C and filtered. The filtrate is then washed and subsequently evaporated to dryness to produce the expected product in a yield of 92%. Example 2: (2S,3aSJaS)'l-{(2S}-2-[(lS)-l-(Ethaxycarbmyt)-butylumma]-pmptonylj-actahydm-lH-melole-2-carboxyticacid The residue obtained in the preceding step (1 kg) is dissolved in 1 litre of methyl¬cyclohexane and the solution is transferred to a hydrogenator; 0.13 kg of 5 % palladium-on-carbon suspended in 0.4 litres of methylcyclohexane are then added, followed by 3.2 litres of water. The mixture is then hydrogenated under a pressure of 0.5 bar at a temperatiu-e of from 15 to 30°C until the theoretical amount of hydrogen has been absorbed. After removal of the catalyst by filtration, the aqueous phase of the filtrate is washed with methylcyclohexane and then lyophilised to produce the expected product in a yield of 94 %. Example 3: (2Sf3aSf 7aS)'l-f(2S)-2~f(lS)-l-(ethaxycarb0nyl)-butylammaJ-pmpmnyl}-octahydm-lH-mdate-2-carboxyttc acid teH-butylamme salt: The lyophilisate obtained in the preceding step (1 kg) is dissolved in 14 litres of ethyl acetate; 0.2 kg of tert-butylamine and 2 litres of ethyl acetate are then added. The suspension obtained is subsequently heated at reflux until complete dissolution is achieved, and the resulting solution is then filtered while hot and cooled, with stirring, to a temperature of 15-20°C. The precipitate obtained is then filtered off, made into a paste again with ethyl acetate, dried and then ground to produce the expected product in a yield of 95 %. WE CLAIM: 1. Process for the industrial synthesis of penndopril of formula (I) and pharmaceutically acceptable salts thereof, characterised in that the benzyl ester of formula (IV): wherein Bn represents the benzyl group, is reacted with the compound of formula (V): in ethyl acetate, in the presence of an amount of from 0.4 to 0.6 mol of 1-hydroxybenzotriazole per mol of compound of formula (TV) eniployed and in the presence of an amount of from 1 to 1.2 mol of dicyclohexylcarbodiimide per mol of compoxmd of formula (IV) employed, in the absence of triethylamine or in the presence of an amount of triethylamine that is less than or equal to 1 mol per mol of compound of formula (IV) employed, at a temperature of from 20 to 77°C, to yield, after isolation, the compound of formula (VI) : wherein Bn represents the benzyl group, the carboxylic group of the heterocycle of which is deprotected by catalytic hydrogenation to yield perindopril of formula (I), which is converted, if desired, into a pharmaceutically acceptable salt. 2. A process as claimed in claim 1, wherein the synthesis of perindopril is in the form of its tertbutylamine salt. 3. A process as claimed in claim 1, wherein the coupling reaction is carried out in the absence of triethylamine. 4. A process as claimed in claim 1, wherein the coupling reaction is carried out in the presence of an amoxmt of triethylamine that is less than or equal to 1 mol per mol of compound of formula (IV) employed. 5. A process as claimed in claim 4, wherein the coupling reaction is carried out in the presence of an amount of triethylamine that is less than or equal to 0.25 mol per mol of compound of formula (IV) employed. 6. A process as claimed in claims 1 to 5, wherein the compound of formula (VI) is obtained with a level of impurities of formulae (VII) and (VIII) that is less than 1.5% (vn) (vni). 7. A process as claimed in claims 1 to 6, wherein the periondopril is obtained with levels of impurities of formulae (11) and (III) that are less than 0.2% and 0.1%, respectively. 8. A probess for the industrial synthesis of perindopril of formula I substantially as herein described with reference to the foregoing examples. FORM 2 THE PATENTS ACT 1970 [39 OF 1970] COMPLETE SPECIFICATION [See Section 10] "NEW PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF" LES* LABORATOIRES SERVIER, of 12 Place de la Defense, 92415 Courbevoie Cedex, France, The following specification particularly describes the nature of the invention and the manner in which it is to be performed :- The present invention relates to a process for the industrial synthesis of perindopril of formula (T): H and pharmaceutically acceptable salts thereof. Perindopril, and also pharmaceutically acceptable salts thereof, and more especially the tert-butylamine salt thereof, have valuable pharmacological properties. Their principal property Hes in the inhibition of the enzyme that converts angiotensin I (or kininase 11), which enables on the one hand prevention of the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II (vasoconstrictor) and oh the other hand prevention of the degradation of bradykinin (vasodilator) to inactive peptide. ■ Those two actions contribute to the beneficial effects of perindopril in cardiovascular disorders, especially arterial hypertension and cardiac insufficiency. Perindopril, its preparation and its therapeutic use have been described in European Patent Specification EP 0 049 658. Given the pharmaceutical interest in that compoimd, it is important to be able to obtain it by an effective industrial synthesising process that can readily be applied on an industrial scale, yielding perindopril in a good yield and, especially, with an excellent degree of purit) The Patent Specification EP 0 308 341 describes the industrial synthesis of perindopril by the coupling of (25',3aS',7aS)-octahydroindole-2-carboxyhc acid benzyl ester with N-[(5)-l- carboxybutyl]-(5)-alanine ethyl ester, followed by deprotection of the carboxylic group of the heterocycle by catalytic hydrogenation. That process has the advantage of yielding perindopril in a good yield from starting materials for which industrial synthesis has already been described. However, the purity of the perindopril obtained by that process is not satisfactory, and necessitates a purification step in order to obtain perindopril of a quality that would allow its use as a pharmaceutical active ingredient. Indeed, under the conditions described in that patent specification the perindopril obtained is contaminated by significant amounts of the impurities of formulae (II) and (III): H H (II) (HI)- The Applicant has now developed a new industrial synthesising process that yields perindopril in a degree of purity that is compatible with its use as a pharmaceutical active ingredient, the levels of impurities of formulae (II) and (III) being less than 0.2 % and 0.1 %, respectively. More specifically, the present invention relates to a process for the industrial synthesis of perindopril which is characterised in that the benzyl ester of formula (IV): wherein Bn Tepresents the benzyl group, is reacted with the compound of formula (V) : in ethyl acetate, in the presence of an amount of from 0.4 to 0.6 mol of 1-hydroxybenzotriazoIe per mol of compound of formula (IV) employed and in the presence of an amount of from 1 to 1.2 mol of dicyclohexylcarbodiimide per mol of compound of formula (IV) employed, in the absence of triethylamine or in the presence of an amonnt of triethylamine that is less than or equal to 1 mol per mol of compound of formula (IV) employed, preferably less than or equal to 0.25 mol per mol of compound of formula (IV) employed, at a temperature of from 20 to 77°C, to yield, after isolation, the compound of formula (VI) wherein Bn represents the benzyl group, the carboxyhc group of the heterocycle of which is deprotected by catalytic hydrogenation to yield perindopril of formula (I), which is converted, if desired, into a pharmaceutically acceptable salt, such as the tert-butylamine salt. The process is of particular interest for the following reasons : The coupling in alkahne medium of the benzyl ester of formula (IV) with the compound of formula (V) has been described in the Patent Specification EP 0 308 341 but, under the conditions described (the use of 3 mols of compound of formula (V), 3 mol of triethylamine, 3.8 mol of 1-hydroxybenzotriazole and 2.9 mol of dicyclo-hexylcarbodiimide per mol of compound of formula (IV) employed), numerous secondary products are formed. In particular, the compound of formula (VI) obtained contains in significant amounts (5 to 15 %) the impurities of formulae (VII) et (VIII) which, when debenzylation is carried out, result in the impurities of formulae (II) and (III) (VII) (VIII). - The Applicant has found, unexpectedly, that the reduction, or even omission, of triethylamine in the coupling step, has made it possible to restrict the levels of impurities of formulae (VII) and (VIII) in the compound of formula (VI) to less than 1.5%. The catalytic hydrogenation of the compound of formula (VI) so obtained yields perindopril of far better purity, and in particular with levels of impurities of formulae (II) and (III) of less than 0.2 % and 0.1 %, respectively. - In addition, the reduction, in the coupling step, of the amount of compound of formula (V), of 1-hydroxybenzotriazole and of dicyclohexylcarbodiimide, enables a yield of compound of formula (VI) to be obtained that is as good as that obtained with larger amounts of reagents, thus making the process far more advantageous on an industrial scale. The Examples below illustrate the invention but do not hmit it in any way. Examvle 1: Benl (2S,3aS, 7aS)-l-{(2S)-2-l(lS)-l-(etha:carbonyl)-butylammo]-pmpianylJ-octahydFa-lH-Mole-2-carboxplate: There are introduced into a reactor, with stirring, 1 kg of (25,3aS',7a5)-octahydroindole-2-carboxylic acid benzyl ester paratoluenesulfonate, 0.06 kg of triethylamine, 4.6 litres of ethyl acetate and then, after stirring for 10 minutes at ambient temperature, 0.52 kg of N-[(5)-ethoxycarbonyl-l-butyl]-(5)-alanine, 0.15 kg of 1-hydroxybenzotriazole and 0.5 kg of dicylohexylcarbodiimide. The heterogeneous mixture is then brought to 30°C for 3 hours while stirring well, and is subsequently cooled to 0°C and filtered. The filtrate is then washed and subsequently evaporated to dryness to produce the expected product in a yield of 92%. Example 2: (2S,3aSJaS)'l-{(2S}-2-[(lS)-l-(Ethaxycarbmyt)-butylumma]-pmptonylj-actahydm-lH-melole-2-carboxyticacid The residue obtained in the preceding step (1 kg) is dissolved in 1 litre of methyl¬cyclohexane and the solution is transferred to a hydrogenator; 0.13 kg of 5 % palladium-on-carbon suspended in 0.4 litres of methylcyclohexane are then added, followed by 3.2 litres of water. The mixture is then hydrogenated under a pressure of 0.5 bar at a temperatiu-e of from 15 to 30°C until the theoretical amount of hydrogen has been absorbed. After removal of the catalyst by filtration, the aqueous phase of the filtrate is washed with methylcyclohexane and then lyophilised to produce the expected product in a yield of 94 %. Example 3: (2Sf3aSf 7aS)'l-f(2S)-2~f(lS)-l-(ethaxycarb0nyl)-butylammaJ-pmpmnyl}-octahydm-lH-mdate-2-carboxyttc acid teH-butylamme salt: The lyophilisate obtained in the preceding step (1 kg) is dissolved in 14 litres of ethyl acetate; 0.2 kg of tert-butylamine and 2 litres of ethyl acetate are then added. The suspension obtained is subsequently heated at reflux until complete dissolution is achieved, and the resulting solution is then filtered while hot and cooled, with stirring, to a temperature of 15-20°C. The precipitate obtained is then filtered off, made into a paste again with ethyl acetate, dried and then ground to produce the expected product in a yield of 95 %. WE CLAIM: 1. Process for the industrial synthesis of penndopril of formula (I) and pharmaceutically acceptable salts thereof, characterised in that the benzyl ester of formula (IV): wherein Bn represents the benzyl group, is reacted with the compound of formula (V): in ethyl acetate, in the presence of an amount of from 0.4 to 0.6 mol of 1-hydroxybenzotriazole per mol of compound of formula (TV) eniployed and in the presence of an amount of from 1 to 1.2 mol of dicyclohexylcarbodiimide per mol of compoxmd of formula (IV) employed, in the absence of triethylamine or in the presence of an amount of triethylamine that is less than or equal to 1 mol per mol of compound of formula (IV) employed, at a temperature of from 20 to 77°C, to yield, after isolation, the compound of formula (VI) : wherein Bn represents the benzyl group, the carboxylic group of the heterocycle of which is deprotected by catalytic hydrogenation to yield perindopril of formula (I), which is converted, if desired, into a pharmaceutically acceptable salt. 2. A process as claimed in claim 1, wherein the synthesis of perindopril is in the form of its tertbutylamine salt. 3. A process as claimed in claim 1, wherein the coupling reaction is carried out in the absence of triethylamine. 4. A process as claimed in claim 1, wherein the coupling reaction is carried out in the presence of an amoxmt of triethylamine that is less than or equal to 1 mol per mol of compound of formula (IV) employed. 5. A process as claimed in claim 4, wherein the coupling reaction is carried out in the presence of an amount of triethylamine that is less than or equal to 0.25 mol per mol of compound of formula (IV) employed. 6. A process as claimed in claims 1 to 5, wherein the compound of formula (VI) is obtained with a level of impurities of formulae (VII) and (VIII) that is less than 1.5% (vn) (vni). 7. A process as claimed in claims 1 to 6, wherein the periondopril is obtained with levels of impurities of formulae (11) and (III) that are less than 0.2% and 0.1%, respectively. 8. A probess for the industrial synthesis of perindopril of formula I substantially as herein described with reference to the foregoing examples.

Documents:

598-mum-2002-cancelled pages(29-11-2004).pdf

598-mum-2002-claims(granted)-(29-11-2004).doc

598-mum-2002-claims(granted)-(29-11-2004).pdf

598-mum-2002-correspondence(16-12-2004).pdf

598-mum-2002-correspondence(ipo)-(4-6-2004).pdf

598-mum-2002-form 1(16-8-2002).pdf

598-mum-2002-form 19(6-4-2004).pdf

598-mum-2002-form 2(granted)-(29-11-2004).doc

598-mum-2002-form 2(granted)-(29-11-2004).pdf

598-mum-2002-form 3(15-12-2004).pdf

598-mum-2002-form 3(16-8-2002).pdf

598-mum-2002-form 3(3-7-2002).pdf

598-mum-2002-power of authority(29-11-2004).pdf

598-mum-2002-power of authority(3-7-2002).pdf